Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tectonic Therapeutic (TECX)
NASDAQ:TECX
RESEARCH TOOLSreports
Tectonic Therapeutic (TECX) Stock Price & Analysis
316 Followers
TECX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.12 - $19.80
Previous Close$16.65
Volume7.24K
Average Volume (3M)24.07K
Market Cap
$245.33M
Enterprise Value$155.07M
Total Cash (Recent Filing)$90.48M
Total Debt (Recent Filing)$224.00K
Price to Earnings (P/E)2.0
Beta1.49
Next Earnings
May 09, 2024EPS Estimate
-$0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.29
Shares Outstanding14,734,323
10 Day Avg. Volume14,147
30 Day Avg. Volume24,066
Standard Deviation0.22
R-Squared0.09
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.72
Price to Sales (P/S)3254.95
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.87K
Enterprise Value/Gross Profit-75.98
Enterprise Value/Ebitda2.94
Forecast
1Y Price Target
$76.00Price Target Upside356.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Tectonic Therapeutic News
PremiumCompany Announcements
Tectonic Therapeutic Announces COO Departure and Severance Terms
PremiumCompany Announcements
Tectonic Therapeutic Updates Investors and Launches Phase 2 Trial
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
TECX FAQ
What was Tectonic Therapeutic’s price range in the past 12 months?
Tectonic Therapeutic lowest stock price was $12.12 and its highest was $19.80 in the past 12 months.
What is Tectonic Therapeutic’s market cap?
Currently, no data Available
When is Tectonic Therapeutic’s upcoming earnings report date?
Tectonic Therapeutic’s upcoming earnings report date is May 09, 2024 which is 74 days ago.
How were Tectonic Therapeutic’s earnings last quarter?
Tectonic Therapeutic released its earnings results on Mar 20, 2024. The company reported -$0.35 earnings per share for the quarter, the consensus estimate of -$0.35 by $0.
Is Tectonic Therapeutic overvalued?
According to Wall Street analysts Tectonic Therapeutic’s price is currently Undervalued.
Does Tectonic Therapeutic pay dividends?
Tectonic Therapeutic does not currently pay dividends.
What is Tectonic Therapeutic’s EPS estimate?
Tectonic Therapeutic’s EPS estimate is -$0.36.
How many shares outstanding does Tectonic Therapeutic have?
Tectonic Therapeutic has 14,734,323 shares outstanding.
What happened to Tectonic Therapeutic’s price movement after its last earnings report?
Tectonic Therapeutic reported an EPS of -$0.35 in its last earnings report, expectations of -$0.35. Following the earnings report the stock price went down -0.794%.
Which hedge fund is a major shareholder of Tectonic Therapeutic?
Among the largest hedge funds holding Tectonic Therapeutic’s share is Aisling Capital Management LP. It holds Tectonic Therapeutic’s shares valued at 1M.
---
Tectonic Therapeutic Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$76.00 (356.46% Upside)
$76.00 (356.46% Upside)
Blogger Sentiment
Bullish
TECX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 26.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $970.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.59%
12-Months-Change
Fundamentals
Return on Equity
42.73%
Trailing 12-Months
Asset Growth
11.26%
Trailing 12-Months
Company Description
Tectonic Therapeutic
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on gene therapy for fabry, gaucher, pompe disease, and cystinosis. These gene therapies, on which the company was founded, were developed by Dr. Jeffrey Medin and Dr. Christopher Paige at the University Health Network. AvroBio launched in 2015, is headed by Co-Founder, President and CEO Geoff Mackay, and is headquartered in Cambridge, MA.
---
TECX Stock 12 Month Forecast
Average Price Target
$76.00
▲(356.46% Upside)
Technical Analysis
Best Analysts Covering TECX
1 Year
---